Výsledky vyhledávání - "Katherine G. Moss"

Akademický článek

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.

Autor: Alastair J King, Marc R Arnone, Maureen R Bleam, Katherine G Moss, Jingsong Yang, Kelly E Fedorowicz, Kimberly N Smitheman, Joseph A Erhardt, Angela Hughes-Earle, Laurie S Kane-Carson, Robert H Sinnamon, Hongwei Qi, Tara R Rheault, David E Uehling, Sylvie G Laquerre

Publikováno v: PLoS ONE, Vol 8, Iss 7, p e67583 (2013)

Mitogen-Activated Protein Kinase (MAPK) pathway activation has been implicated in many types of human cancer. BRAF mutations that constitutively activate MAPK signalling and bypass the need for upstream stimuli occur with high prevalence in melanoma,

Externí odkaz: https://doaj.org/article/f2ff4fc2ea6640b3bec689c5d38dc373

Zobrazit plný text záznamu

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

Autor: Maureen R. Bleam, Sylvie Laquerre, Katherine G. Moss, Cynthia M. Rominger, Roland S. Annan, Francesca Zappacosta, Swarupa G Kulkarni, David Sutton, Arthur Groy, Aidan G. Gilmartin, Symon G. Erskine, Elisabeth A. Minthorn, Kelly E. Fisher, Jingsong Yang

Publikováno v: Clinical Cancer Research. 17:989-1000

Purpose: Despite their preclinical promise, previous MEK inhibitors have shown little benefit for patients. This likely reflects the narrow therapeutic window for MEK inhibitors due to the essential role of the P42/44 MAPK pathway in many nontumor ti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99320e3da440ba1e4a7f2f6c577bf5cb
https://doi.org/10.1158/1078-0432.ccr-10-2200

Zobrazit plný text záznamu

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models

Autor: Ken A. Newlander, Denis R. Patrick, Dashyant Dhanak, Jingsong Yang, Mary Ann Hardwicke, Catherine A. Oleykowski, Jerry L. Adams, Zhihong Lai, David Sutton, Jamin Wang, Ramona Plant, Qiaoyin Liao, Katherine G. Moss

Publikováno v: Molecular Cancer Therapeutics. 8:1808-1817

The protein kinases, Aurora A, B, and C have critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. GSK1070916, is a novel ATP competitive inhibitor that is highly potent and selective for Aurora B/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cedbacc1a81457f1d1b91b5a6ac65011
https://doi.org/10.1158/1535-7163.mct-09-0041

Zobrazit plný text záznamu

Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo

Autor: Juthamas Sukbuntherng, Catherine Magill, John Eksterowicz, Doris Graupe, Michael J. Green, Penglie Zhang, Hyunjin M. Kim, Martin Sendzik, Peter Sabbatini, Jason Oeh, Jeffrey R. Spencer, Stacie A. Dalrymple, Peter R. Young, Katherine G. Moss, Andrew G. Myers, Neil H. Squires

Publikováno v: Bioorganic & Medicinal Chemistry Letters. 16:4884-4888

Novel analogs of (-)-saframycin A are described. The analogs are shown to be potent inhibitors of the in vitro growth of several tumor cells in a broad panel and promising as leads for further optimization. The first in vivo studies in a solid tumor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211f339c2f46146df07ee8a6fabe3a5f
https://doi.org/10.1016/j.bmcl.2006.06.085

Zobrazit plný text záznamu

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

Autor: A. Douglas Laird, Angela Barone, Dirk B. Mendel, Julie M. Cherrington, Guangmin Li, Katherine G. Moss, Olga Potapova, Michelle Nannini

Publikováno v: Molecular Cancer Therapeutics. 5:1280-1289

Recent achievements in the development of multitargeted molecular inhibitors necessitate a better understanding of the contribution of activity against individual targets to their efficacy. SU11248, a small-molecule inhibitor targeting class III/V re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb7b56e1837fbb8cf98abe1e90e4d5e2
https://doi.org/10.1158/1535-7163.mct-03-0156

Zobrazit plný text záznamu

SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice

Autor: James G. Christensen, Julie M. Cherrington, Guangmin Li, Kimberly A. Smith, Dirk B. Mendel, Xiaohua Xin, Sharianne G. Louie, Jeremy Carver, A. Douglas Laird, Katherine G. Moss

Publikováno v: The FASEB Journal. 16:681-690

SU6668 is a small molecule inhibitor of the angiogenic receptor tyrosine kinases Flk-1/KDR, PDGFRbeta, and FGFR1. In mice, SU6668 treatment resulted in regression or growth arrest of all large established human tumor xenografts examined associated wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6598dfa5ed846b58b06cc4c7d601bad3
https://doi.org/10.1096/fj.01-0700com

Zobrazit plný text záznamu

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions

Autor: Kelly E. Fedorowicz, Hongwei Qi, Angela Hughes-Earle, Joseph A. Erhardt, Robert H. Sinnamon, Marc R. Arnone, Tara Renae Rheault, Katherine G. Moss, Alastair J. King, Sylvie Laquerre, Jingsong Yang, David E. Uehling, Laurie S. Kane-Carson, Maureen R. Bleam, Kimberly N. Smitheman

Publikováno v: PLoS ONE
PLoS ONE, Vol 8, Iss 7, p e67583 (2013)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83f0aea7acc667312812b279f91c8d9
https://pubmed.ncbi.nlm.nih.gov/23844038

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání